#1 Clinical Trials Search in Europe

Dabigatran

This article examines the use of dabigatran, a blood-thinning medication, in clinical trials for various medical conditions. Dabigatran, also known by its brand name Pradaxa, has been studied for its effectiveness in preventing blood clots and reducing the risk of stroke in patients with atrial fibrillation. We’ll explore the key findings from several clinical trials, focusing on the drug’s safety profile, dosing regimens, and potential interactions with other medications.

Table of Contents

What is Dabigatran?

Dabigatran, also known by its brand name Pradaxa, is a medication used to prevent blood clots and reduce the risk of stroke in patients with certain heart conditions[1]. It belongs to a class of drugs called direct thrombin inhibitors, which work by preventing the formation of blood clots[2].

Uses of Dabigatran

Dabigatran is primarily used for the following conditions:

  • Atrial Fibrillation: It helps prevent stroke and blood clots in patients with a heart rhythm disorder called atrial fibrillation[1].
  • Venous Thromboembolism (VTE): Dabigatran is used to prevent blood clots in patients undergoing hip or knee replacement surgery[2].
  • Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): It can be used to treat and prevent the recurrence of these types of blood clots[2].

How Dabigatran Works

Dabigatran works by directly inhibiting thrombin, an enzyme in the blood that plays a crucial role in blood clot formation. By blocking thrombin, dabigatran helps prevent the formation of blood clots, reducing the risk of stroke and other clot-related complications[2].

Dosage and Administration

The dosage of dabigatran can vary depending on the specific condition being treated and the patient’s kidney function. Common dosages include:

  • 150 mg twice daily for most patients with atrial fibrillation[1]
  • 75 mg twice daily for patients with reduced kidney function[3]
  • 110 mg twice daily as an alternative dose for some patients[1]

It’s important to take dabigatran exactly as prescribed by your doctor. The medication is usually taken with or without food, and it’s crucial not to miss doses to maintain its effectiveness[1].

Safety and Side Effects

Like all medications, dabigatran can cause side effects. The most common and important side effects to be aware of include:

  • Bleeding: As an anticoagulant, dabigatran increases the risk of bleeding. This can range from minor bleeding (such as nosebleeds or bruising easily) to more serious bleeding events[2].
  • Gastrointestinal symptoms: Some patients may experience stomach discomfort, indigestion, or nausea[1].
  • Allergic reactions: Although rare, some people may have an allergic reaction to dabigatran[4].

It’s important to report any unusual bleeding or symptoms to your healthcare provider immediately[2].

Interactions with Other Medications

Dabigatran can interact with various medications, potentially affecting its effectiveness or increasing the risk of side effects. Some notable interactions include:

  • Other blood thinners: Taking dabigatran with other anticoagulants can significantly increase the risk of bleeding[2].
  • Certain antibiotics: Some antibiotics can affect the levels of dabigatran in the body[5].
  • Some antifungal medications: These can also impact dabigatran levels[5].
  • Certain HIV medications: Some drugs used to treat HIV can interact with dabigatran[6].

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions[5].

Special Considerations

There are some important considerations when taking dabigatran:

  • Surgery or medical procedures: Dabigatran may need to be temporarily stopped before certain surgeries or medical procedures to reduce the risk of bleeding. Always inform your healthcare providers that you are taking dabigatran[7].
  • Kidney function: The dosage of dabigatran may need to be adjusted based on your kidney function. Regular kidney function tests may be necessary[3].
  • Pregnancy and breastfeeding: The safety of dabigatran during pregnancy and breastfeeding is not well established. Discuss with your doctor if you are pregnant, planning to become pregnant, or breastfeeding[1].
  • Missed doses: If you miss a dose, take it as soon as you remember. However, if it’s close to the time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for a missed one[1].
Study Focus Key Findings Safety Considerations
Atrial Fibrillation Dabigatran studied for stroke and thromboembolism prevention in patients undergoing left atrial catheter ablation Monitored for major adverse bleeding risks and thromboembolic event rates
Drug Interactions Investigated interactions between dabigatran and other drugs like odalasvir, simeprevir, and quizartinib Assessed changes in dabigatran’s pharmacokinetics when combined with other medications
Venous Thromboembolism Evaluated different doses of dabigatran for preventing VTE in patients undergoing hip or knee replacement surgery Compared efficacy and safety to enoxaparin, focusing on bleeding events and VTE occurrence
Bioequivalence Compared new formulations of dabigatran to existing ones for bioequivalence Assessed absorption rates and overall exposure in healthy subjects

FAQ

  • What is dabigatran used for in clinical trials? Dabigatran is primarily studied for preventing blood clots and reducing stroke risk in patients with atrial fibrillation. It's also been investigated for preventing venous thromboembolism in patients undergoing hip or knee replacement surgery.
  • How is dabigatran administered in clinical trials? In the trials reviewed, dabigatran was typically administered orally in capsule form. Dosages varied from 50 mg to 300 mg, given either once or twice daily, depending on the specific study and patient characteristics.
  • What are the main safety concerns with dabigatran? The primary safety concern with dabigatran is the risk of bleeding events. Clinical trials closely monitored for major bleeding events, clinically significant bleeding, and minor bleeding events.
  • How does dabigatran compare to other anticoagulants in trials? Some trials compared dabigatran to enoxaparin, another anticoagulant. The studies aimed to establish the efficacy and safety profile of dabigatran in relation to existing treatments.
  • Are there any drug interactions studied with dabigatran? Yes, some trials investigated potential drug interactions. For example, one study looked at the interaction between dabigatran and quizartinib, focusing on how quizartinib might affect dabigatran's absorption and concentration in the body.

Ongoing Clinical Trials on Dabigatran

  • Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Effects of Ticagrelor and Rivaroxaban in Patients with Atrial Fibrillation After Coronary Stent Surgery

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Denmark Finland France Germany Greece +5

  • Study on Edoxaban and Drug Combination for Patients with Atrial Fibrillation Needing Anticoagulation After Cardiac Surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Stopping Anticoagulants in Atrial Fibrillation Patients After Surgery: Warfarin, Rivaroxaban, Apixaban, Edoxaban, Dabigatran, and Drug Combination

    Recruiting

    3 1 1 1
    Investigated drugs:
    Denmark Sweden

Glossary

  • Atrial Fibrillation: An irregular and often rapid heart rate that can increase the risk of stroke and other heart-related complications.
  • Venous Thromboembolism (VTE): A condition where blood clots form in the veins, typically in the legs or lungs.
  • Deep Vein Thrombosis (DVT): A blood clot that forms in a deep vein, usually in the leg.
  • Pulmonary Embolism (PE): A blockage in one of the pulmonary arteries in the lungs, often caused by blood clots that travel from the legs or other parts of the body.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Bioequivalence: The absence of a significant difference in the rate and extent to which the active ingredient becomes available at the site of drug action.
  • P-gp (P-glycoprotein): A protein in the body that helps move drugs and other substances out of cells, potentially affecting how much of a drug enters the bloodstream.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used to assess the effectiveness and safety of medications.
  • Cmax: The maximum concentration of a drug in the blood after it has been administered.
  • Tmax: The time it takes for a drug to reach its maximum concentration in the blood.

References

  1. https://clinicaltrials.gov/study/NCT01774370
  2. https://clinicaltrials.gov/study/NCT01225822
  3. https://clinicaltrials.gov/study/NCT05673889
  4. https://clinicaltrials.gov/study/NCT04433481
  5. https://clinicaltrials.gov/study/NCT02945020
  6. https://clinicaltrials.gov/study/NCT05064800
  7. https://clinicaltrials.gov/study/NCT01976507